Retroviral vectors for vaccine development: induction of HIV-1-specific humoral and cellular immune responses in rhesus macaques using a novel MLV(HIV-1) pseudotype vector

Journal of Biotechnology

Volumn 124, Issue 3, 2006, Pages 615-625

  Neumann, Jeanette ^a   Stitz, Jörn ^a,b   König, Renate ^a   Seibold, Eric ^c   Norley, Stephen ^c   Flory, Egbert ^a   Cichutek, Klaus ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

^b ETH ZURICH   (Switzerland)

^c ROBERT KOCH INSTITUTE   (Germany)

Author keywords

HIV antigens; Immunization; Retroviral vector; Rhesus macaque model; SHIV

Indexed keywords

BIOASSAY; BIOTECHNOLOGY; BLOOD; DISEASE CONTROL; GENE TRANSFER; IMMUNIZATION;

HIV-ANTIGENS; RETROVIRAL VECTOR; RHESUS MACAQUE MODEL; SHIV;

VACCINES;

CD4 ANTIGEN; NERVE GROWTH FACTOR RECEPTOR; RETROVIRUS VECTOR; REV PROTEIN; TRANSACTIVATOR PROTEIN; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VPU PROTEIN;

ANIMAL CELL; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN IMMUNODEFICIENCY VIRUS 1 PSEUDOTYPE VECTOR; HUMORAL IMMUNITY; HYBRID; IMMUNE RESPONSE; IMMUNIZATION; INOCULATION; LENTIVIRINAE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS;

AIDS VACCINES; ANIMALS; ANTIBODY FORMATION; CLONING, MOLECULAR; GENETIC VECTORS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HIV-1; MACACA MULATTA; RETROVIRIDAE; TRANSFECTION;

HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS; MACACA MULATTA; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33745501012     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2006.01.032     Document Type: Article

References (23)

1. +. Hum. Gene Ther. 9 (1998) 1561-1570
2. Bruce C.B., Akrigg A., Sharpe S.A., Hanke T., Wilkinson G.W., and Cranage M.P. Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL imme responses in mice. J. Gen. Virol. 80 (1999) 2621-2628
3. Crotty S., Lohman B.L., Lu F.X.-S., Tang S.B., Miller C.J., and Andino R. Muscosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: stimulation of humoral, mucosal, and cellular immunity. J. Virol. 73 11 (1999) 9485-9495
4. Dong M., Zhang P.F., Grieder F., Lee J., Krishnamurthy G., VanCott T., Broder C., Polonis V.R., Yu X.F., Shao Y., Faix D., Valente P., and Quinnan G.V. J. Virol. 77 5 (2003) 3119-3130
5. Giri M., Ugen K.E., and Weiner D.B. DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin. Microbiol. Rev. 17 2 (2004) 370-389
6. Mammano F., Salvatori F., Indraccolo S., De Rossi A., Chieco-Bianchi L., and Gottlinger H.G. Truncation of the human immunodeficiency virus type 1 envelope glycoprotein allows efficient pseudotyping of murine leukemia virus particles and gene transfer into CD4+ cells. J. Virol. 71 4 (1997) 3341-3345
7. Muhlebach M.D., Schmitt I., Steidl S., Stitz J., Schweizer M., Blankenstein T., Cichutek K., and Uckert W. Transduction efficiency of MLV but not HIV-1 vectors is pseudotype dependent on human primary T lymphocytes. J. Mol. Med. 81 12 (2003) 801-810
8. Negri D.R.M., Baroncelli S., Catone S., Comini A., Michelini Z., Maggiorella M.T., Sernicola L., Crostarosa F., Belli R., Mancini M.G., Farcomeni S., Fagrouch Z., Ciccozzi M., Boros S., Liljestrom P., Norley S., Heeney J., and Titti F. Protective efficacy of a multicomponent vector vaccine in cynomolgusmonkeys after intrarectal simian immunodeficiency virus challenge. J. Gen. Virol. 85 (2004) 1191-1201
9. Nehring, D., Gonzales, R., Pörtner, R, Czermak, P., 2006. Experimental and modeling study of different process modes for retroviral production in fixed bed reactor. J. Biotechnol. 122 (2), 239-253.
10. Nishimura Y., Igarashi T., Donau O.K., Buckler-White A., Buckler C., Lafont B.A.P., Goeken R.M., Goldstein S., Hirsch V.M., and Martin M.A. Highly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in Rhesus monkeys, explaining their divergent clinical courses. Proc. Natl. Acad, Sci. USA 101 33 (2004) 12324-12329
11. Polo J.M., and Dubensky Jr. T.W. Virus-based vectors for human vaccine applications. Drug Discov. Today 7 13 (2002) 719-727
12. Przybylowski, M., Hakakha, A., Stefanski, J., Hodges, J., Sadelain, M., Rivier, I., 2005. Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in cell factories. Gene Ther. 13, 95-100.
13. Ramsburg E., Rose N.F., Marx P.A., Mefford M., Nixon D.F., Moretto W.J., Montefiori D., Earl P., Moss B., and Rose J.K. Highly efficient control of an AIDS virus challenge by using vesicular stomatitis virus and modified vaccinia virus ankara vaccine vectors in a single-boost protocol. J. Virol. 78 8 (2004) 3930-3940
14. Reimann, K.A., Li, J.T., Veazey, R., Halloran, M., Park, I.-W., Karlsson, G.B., Sodorski, J., Letvin, N.L., 1996. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 70 (10), 6922-6928.
15. Schnierle B.S., Stitz J., Bosch V., Nocken F., Merget-Millitzer H., Engelstadter M., Kurth R., Groner B., and Cichutek K. Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells. Proc. Natl. Acad. Sci. USA 94 16 (1997) 8640-8645
16. Steidl S., Schule S., Muhlebach M.D., Stitz J., Boller K., Cichutek K., and Schweizer M. Genetic engineering of onco/lentivirus hybrids results in formation of infectious but not of replication-competent viruses. J. Gen. Virol. 85 (2004) 665-678
17. Steidl S., Stitz J., Schmitt I., Konig R., Flory E., Schweizer M., and Cichutek K. Coreceptor switch of MLV(SIVagm) pseudotype vectors by V3-loop exchange. Virology 300 (2002) 205-216
18. Stitz J., Muller P., Merget-Millitzer H., and Cichutek K. High-titer retroviral pseudotype vectors for the specific targeting of human CD-positive cells. Biogenic Amines 14 (1998) 407-424
19. Stitz J., Steidl S., Merget-Millitzer H., Konig R., Muller P., Nocken F., Engelstadter M., Bobkova M., Schmitt I., Kurth R., Buchholz C.J., and Cichutek K. MLV-derived retroviral vectors selective for CD4-expressing cells and resistant to neutralisation by sera from HIV-infected patients. Virology 267 2 (2000) 229-236
20. Vajdy M., Gardner J., Neidleman J., Cuadra L., Greer C., Perri S., O'Haga D., and Polo J.M. Human immunodeficiency virus type 1 Gag-specific vaginal immunity and protection after local immunization with sindbis virus-based replicon particles. J. Infect. Dis. 184 12 (2001) 1613-1616
21. Vazquez Blomquist D., Green P., Laidlaw S.M., Skinner M.A., Borrow P., and Duarte C.A. Induction of a strong HIV-specific CD8+ T cell response in mice using flowpox virus vector expressing an HIV-1 multi-CTL-epitope polypeptide. Viral Immunol. 15 2 (2002) 337-356
22. Whitney J.B., and Ruprecht R.M. Live attenuated HIV vaccines: pitfalls and prospects. Curr. Opin. Infect. Dis. 17 1 (2004) 17-26
23. Wysocki P.J., Grabarczyk P., and Mackeiwicz A. Recent developments in retroviral gene delivery systems. Expert. Opin. Biol. Ther. 1 6 (2001) 911-913